ID   WM47
AC   CVCL_C280
SY   WM-47; WM 47
DR   cancercelllines; CVCL_C280
DR   GEO; GSM186491
DR   GEO; GSM186492
DR   Progenetix; CVCL_C280
DR   Rockland; 51398
DR   Wikidata; Q54994307
RX   PubMed=6159966;
WW   Info; Wistar; -; https://www.wistar.org/our-scientists/meenhard-herlyn
CC   Part of: Wistar Institute melanoma cell line collection.
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Wistar).
CC   Omics: Transcriptomics; Microarray.
CC   Discontinued: Rockland; 51398; true.
CC   Derived from site: Metastatic; Not specified.
ST   Source(s): Wistar
ST   Amelogenin: X,Y
ST   CSF1PO: 10
ST   D13S317: 10,12
ST   D16S539: 8,12
ST   D21S11: 28,29
ST   D5S818: 11
ST   D7S820: 8,11
ST   TH01: 9.3
ST   TPOX: 10,11
ST   vWA: 16,17
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 10-04-25; Version: 22
//
RX   PubMed=6159966;
RA   Herlyn M., Clark W.H. Jr., Mastrangelo M.J., Guerry D. 4th,
RA   Elder D.E., LaRossa D., Hamilton R., Bondi E., Tuthill R.,
RA   Steplewski Z., Koprowski H.;
RT   "Specific immunoreactivity of hybridoma-secreted monoclonal
RT   anti-melanoma antibodies to cultured cells and freshly derived human
RT   cells.";
RL   Cancer Res. 40:3602-3609(1980).
//